Sanofi (NASDAQ:SNY) Research Coverage Started at Wolfe Research

Wolfe Research began coverage on shares of Sanofi (NASDAQ:SNY) in a research note published on Friday, Marketbeat Ratings reports. The firm issued a peer perform rating on the stock.

Several other research firms have also recently weighed in on SNY. Wall Street Zen cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Morgan Stanley set a $49.00 target price on shares of Sanofi in a research report on Wednesday, July 8th. Royal Bank Of Canada started coverage on shares of Sanofi in a research report on Tuesday, September 8th. They set a “sector perform” rating for the company. Weiss Ratings cut shares of Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, August 3rd. Finally, HSBC reissued a “buy” rating on shares of Sanofi in a report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $49.50.

Sanofi Price Performance

Sanofi stock opened at $40.07 on Friday. Sanofi has a 52 week low of $39.18 and a 52 week high of $52.68. The business has a 50-day simple moving average of $42.99 and a 200 day simple moving average of $43.99. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21. The stock has a market cap of $97.15 billion, a price-to-earnings ratio of 20.98, a PEG ratio of 1.23 and a beta of 0.33.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 30th. The company reported $2.41 earnings per share for the quarter. The firm had revenue of $13.36 billion for the quarter. Sanofi had a return on equity of 14.19% and a net margin of 8.66%. The business’s revenue was up 16.0% on a year-over-year basis. During the same period in the previous year, the business earned $3.24 EPS. On average, research analysts forecast that Sanofi will post 5.00 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sanofi

Several institutional investors have recently modified their holdings of the company. Physician Wealth Advisors Inc. grew its stake in shares of Sanofi by 180.5% during the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after buying an additional 379 shares during the last quarter. Leonteq Securities AG increased its holdings in shares of Sanofi by 95.8% in the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after buying an additional 297 shares during the period. Western Wealth Management LLC bought a new stake in shares of Sanofi in the 1st quarter valued at about $29,000. Fairway Wealth LLC bought a new stake in shares of Sanofi in the 1st quarter valued at about $32,000. Finally, Purpose Unlimited Inc. purchased a new stake in Sanofi during the 4th quarter valued at about $36,000. 14.03% of the stock is currently owned by institutional investors.

About Sanofi

Sanofi is a France-based global healthcare company that develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. Its portfolio focuses on areas including immunology, rare diseases, vaccines, diabetes and other chronic conditions, as well as specialized treatments for selected neurological and inflammatory disorders.

The company is known for products such as Dupixent, a biologic used to treat several inflammatory conditions, and a broad range of vaccines marketed through its Sanofi Pasteur business.